Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Detection and targeted sequencing of influenza A virus subtypes using Dutch wastewater samples from influenza season 2023-2024 and 2024-2025.

The Science of the total environment·2026

Same author

Augmedicine: Ultrasound: Training in ultrasound using XR - a randomized controlled trial.

BMC medical education·2026

Same author

Comprehensive wastewater genomic surveillance in the Netherlands: insights into country-wide SARS-CoV-2 lineage dynamics and implications for future surveillance.

BMC public health·2025

Same author

Development and Face and Content Validation of Augmedicine: Ultrasound-An Extended Reality Application for Ultrasound Training.

Australasian journal of ultrasound in medicine·2025

Same author

Impact of a Digital Scribe System on Clinical Documentation Time and Quality: Usability Study.

JMIR AI·2024

Same author

Long-term wastewater monitoring of SARS-CoV-2 viral loads and variants at the major international passenger hub Amsterdam Schiphol Airport: A valuable addition to COVID-19 surveillance.

The Science of the total environment·2024

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Alternative strategies for Clostridium difficile infection.

Martijn P Bauer¹, Jaap T van Dissel

¹Department of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

International Journal of Antimicrobial Agents

|March 24, 2009

Summary

Clostridium difficile infection often relapses after antibiotic treatment due to gut microflora disruption. Current non-antibiotic therapies lack proven benefits, necessitating further clinical trials.

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

Related Experiment Videos

Last Updated: Jun 24, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

Area of Science:

Microbiology
Infectious Diseases
Gastroenterology

Background:

Antibiotics are standard for Clostridium difficile infection (CDI) but lead to frequent relapses.
Relapses are linked to antibiotic-induced disruption of protective gut microflora.
Effective non-antibiotic strategies for CDI prevention and treatment are needed.

Purpose of the Study:

To review non-antibiotic strategies for Clostridium difficile infection.
To assess the current evidence for alternative CDI therapies.
To highlight the need for rigorous clinical trials.

Main Methods:

Literature review of non-antibiotic approaches for CDI.
Analysis of existing therapeutic options and their reported efficacy.
Identification of research gaps in CDI treatment.

Main Results:

Various non-antibiotic strategies exist, including probiotics, immunotherapy, and fecal transplantation.
Currently, no alternative therapy has demonstrated significant proven benefit in preventing or treating CDI.
Evidence supporting these alternative treatments is limited and often anecdotal.

Conclusions:

Non-antibiotic approaches for CDI show limited success to date.
Prospective randomized trials are essential to validate the efficacy of alternative CDI therapies.
Further research is critical to develop effective treatments beyond conventional antibiotics.